Intellia Therapeutics Investor Presentation — November 2021

Document content

Intellia Therapeutics’ Legal Disclaimer

This presentation contains “forward -looking statements” ofIntellia Therapeutics, Inc.(“Intellia”, “we” or“our”) within themeaning ofthePrivate Securities Litigation Reform Act

of1995 .These forward -looking statements include, butarenotlimited to,express orimplied statements regarding Intellia’s beliefs andexpectations regarding our:ability to

complete clinical studies forNTLA -2001 forthetreatment oftransthyretin (“ATTR”) amyloidosis, successfully submit additional regulatory applications inother countries, and

evaluate NTLA -2001 inabroader ATTR population; clinical data from theongoing single -ascending dose portion ofthePhase 1study evaluating NTLA -2001 ;ability toinitiate

aclinical trialforNTLA -5001 forthetreatment ofacute myeloid leukemia (“AML”) bytheendof2021; ability togenerate data todemonstrate NTLA -5001 asapotential best-in-

class engineered Tcelltherapy designed totreat allgenetic subtypes ofAML;plans toevaluate inpreclinical studies thepotential useofNTLA -5001 totreat Wilms’ Tumor 1

(“WT 1”)-positive solid tumors ;expectation toenroll apatient inaclinical study forNTLA -2002 forthetreatment ofhereditary angioedema (“HAE”) in2021 ;expectations of

evaluating safety, tolerability andmeasures ofactivities ofNTLA -2002 inpatients withHAE;plans tonominate atleast oneadditional development candidate in2021 ;plans to

nominate anallogeneic celltherapy candidate in1H2022 ;plans toadvance andcomplete preclinical studies forourresearch programs ;development ofourmodular platform

toadvance ourcomplex genome editing capabilities ;further development ofourproprietary genome editing tools forresearch and therapeutic development, including

sequential editing andbase editing; presentation ofadditional data atupcoming scientific conferences, andother preclinical data in2021 ;advancement andexpansion ofour

CRISPR/Cas 9technology todevelop human therapeutic products ;ability tomaintain andexpand ourrelated intellectual property portfolio, andavoid oracquire rights tovalid

intellectual property ofthird parties ;ability todemonstrate ourplatform’s modularity andreplicate orapply results achieved inpreclinical studies, including those inourATTR,

AML, andHAE programs, inanyfuture studies, including human clinical trials ;ability todevelop other invivoorexvivocelltherapeutics ofalltypes, andthose targeting WT1in

AML inparticular, using CRISPR/Cas 9technology ;ability tooptimize theimpact ofourcollaborations onourdevelopment programs, including butnotlimited toour

collaboration withRegeneron Pharmaceuticals, Inc.including ourco-development programs forhemophilia Aandhemophilia B;Regeneron’s ability tosuccessfully co-develop